Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
7 Hills Pharma, LLC
Seagen Inc.
KaliVir Immunotherapeutics
iOnctura
Sotio Biotech Inc.
M.D. Anderson Cancer Center
Endeavor Biomedicines, Inc.
Azienda Ospedaliero-Universitaria di Parma
Novartis
Kezar Life Sciences, Inc.
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Seattle Children's Hospital
Actym Therapeutics, Inc.
Incyte Corporation
Numab Therapeutics AG
NuCana plc
Medicenna Therapeutics, Inc.
Turnstone Biologics, Corp.
SOLTI Breast Cancer Research Group
Checkpoint Therapeutics, Inc.
BerGenBio ASA
Aminex Therapeutics, Inc.
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
University of California, San Diego
Pfizer
Memorial Sloan Kettering Cancer Center
NGM Biopharmaceuticals, Inc
Massachusetts General Hospital
Rain Oncology Inc
Western Sydney Local Health District
Seagen Inc.
Jules Bordet Institute
Quadriga Biosciences, Inc.
Xencor, Inc.
Incyte Corporation
AbbVie
Infinity Pharmaceuticals, Inc.
Novartis
MacroGenics
Incyte Corporation
Incyte Corporation
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Shenzhen BinDeBio Ltd.
Case Comprehensive Cancer Center
Novartis